BBBarbara Bayeh

Barbara Bayeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Barbara Bayeh has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mortality in Behçet’s Syndrome in a non-endemic population: a 25-year cohort study

    by Mônica Raquel de Souza Aquino, Barbara Bayeh, Carolina Ejnisman, Fabio Augusto da Rocha Specian, Rafael Bassara Macedo, Pedro Cargnelutti de Araujo, Guilherme Diogo Silva, Gisela Tinone, Rafael Alves Cordeiro, Thiago Quadrante Freitas, et al.

    Mortality in Behçet’s syndrome (BS) has been consistently associated with neurological and vascular involvement in studies from endemic regions. However, data from non-endemic countries remain limited. This study aimed to evaluate long-term mortality and identify factors associated with mortality in a large Brazilian cohort of patients with BS. We conducted a retrospective cohort study including 303 adult patients diagnosed with BS and followed at a tertiary referral center in São Paulo, Brazil, between January 2000 and December 2024. Demographic, clinical, comorbidity, and treatment data were collected. Mortality rates were assessed, and factors associated with mortality were analyzed using unadjusted Cox proportional hazards models, with hazard ratios (HRs) and 95% confidence intervals (CIs). Among the 303 patients included, 61.6% were female, with a median follow-up of 117 months (IQR 55–184). A total of 162 patients (53.4%) were lost to follow-up. Eight deaths (2.6%) occurred during the study period. Given the limited number of events, only exploratory, unadjusted analyses were performed. Pulmonary artery aneurysm (HR 28.44, 95% CI 3.32–243.52; p = 0.002), central nervous system (CNS) parenchymal involvement (HR 6.81, 95% CI 1.65–28.06; p = 0.008), diabetes mellitus (HR 6.72, 95% CI 1.67–27.03; p = 0.007), and malignancy (HR 8.81, 95% CI 2.02–38.50; p = 0.004) were associated with increased mortality. Our exploratory analyses suggest that vascular and neurological involvement, particularly pulmonary artery aneurysm and CNS parenchymal disease, may be associated with increased mortality in our population.

  • Open Access

    Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center

    by Barbara Bayeh, Fanny Reyes-Neira, Karina Rossi Bonfiglioli, Nadia Emi Aikawa, Ana Paula Luppino Assad, Renata Miossi, Fernando Henrique Carlos de Souza, Carlos Emilio Insfran, Henrique Ayres Mayrink Giardini, Emily Figueiredo Neves Yuki, et al.

  • Open Access

    Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study

    by Fanny Alcira Reyes Neira, Barbara Bayeh, Karina Rossi Bonfiglioli, Nadia Emi Aikawa, Ana Paula Luppino Assad, Renata Miossi, Fernando Henrique Carlos de Souza, Carlos Emilio Insfrán, Henrique Ayres Mayrink Giardini, Emily Figueiredo Vieira Neves Yuki, et al.

    Aim: The use of anti-TNF drugs is well-established for treating axial spondyloarthritis (axSpA). The introduction of biosimilars offers a more accessible alternative, but data on the switching of adalimumab biosimilars in the axSpA population remain somewhat controversial and are limited to SB5 and ABP 501 and to the European population. This study aims to evaluate the clinical efficacy of switching from originator adalimumab to the biosimilar adalimumab-AACF in Latin American axSpA patients over a 12-month period in a real-life analysis. Methods: This observational study included patients with axSpA who had been treated with originator adalimumab for at least three months and switched to the biosimilar. Disease activity parameters and C-reactive protein (CRP) levels were assessed at baseline (T0) and compared at 6 (T6) and 12 months (T12) following the switch. Results: Twenty-eight patients were included, with a mean duration of originator adalimumab use of 87.6 months. Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP remained stable when comparing T0 to T6 [1.56 (± 0.88) vs. 1.50 (± 0.82), P = 0.73] and T12 [1.56 (± 0.88) vs. 1.26 (± 0.86), P = 0.13]. A similar pattern was observed for ASDAS-erythrocyte sedimentation rate (ESR; P > 0.05) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; P > 0.05). The rate of remission/low disease activity was consistent, recorded at 71.4% at baseline, 78.6% at T6 (P = 0.62) and 78.6% at T12 (P = 0.68). CRP levels did not show significant variation (P > 0.05) across time points. Notably, the one-year drug retention rate was 94.6%. Conclusions: This real-world study highlights for the first time the feasibility and efficacy of transitioning from originator adalimumab to biosimilar AACF in axSpA, providing support for its use in long-term management and offering enhanced accessibility without compromising therapeutic outcomes. These results add valuable Latin American data to the body of evidence on biosimilar integration into clinical practice.